Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.45 |
| ▸ | GABRD | O14764 | 4/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.45 |
| ▸ | GABRE | P78334 | 4/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365364 | 0.89 | PAX8 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3365407 | 0.87 | PAX8 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3363458 | 0.83 | CHRNB2 (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3363541 | 0.83 | PAX8 (0.42) | PAX8PTPN11CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1310372 | 0.79 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22032169 | 0.79 | GABRA1 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30830643 | 0.77 | PPARA (0.48) | PAX8BRD4CREBBP | |
| SCHEMBL8018111 | 0.77 | PAX8 (0.55) | PAX8CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3364676 | 0.77 | PAX8 (0.38) | PAX8PTPN11CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL483964 | 0.75 | PAX8 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303503-B1 | ANILINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-6683201-B2 | FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| EP-1303503-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | LSS, CYP51A1, CYP46A1 | GABRP 4023/4885GABRD 3865/4885GABRA1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.